EBR Systems Reports Strong Q1 2026 Performance
Last week, the team at Bell Potter released updated guidance on ASX small-cap stock EBR Systems Inc (ASX: EBR) following the company’s announcement of a preliminary version of its operating metrics. EBR Systems has developed its patented Wireless Stimulation Endocardially (WiSE) technology for the treatment of cardiac rhythm disease and to eliminate the need for cardiac pacing leads when delivering cardiac resynchronisation therapy.
What did EBR Systems report? The company revealed strong growth in commercial cases during Q1 2026. It also stated that its WiSE® System was successfully implanted in 41 commercial patients during the quarter, bringing the total implants across the pilot phase and Limited Market Release to 71.
John McCutcheon, EBR Systems’ President & Chief Executive Officer, highlighted impressive progress across both commercial and clinical programs during Q1 2026. He noted that case volumes increased strongly during the quarter, reflecting growing physician experience, expanding site readiness, and the steady execution of the Limited Market Release.
The company also continued to advance important clinical initiatives, with further enrolment in both the WiSE-UP post-approval study and the TLC-AU feasibility study, helping to expand the body of evidence supporting the WiSE System across a broader patient population.
This news prompted positive share price movement, with EBR Systems shares closing at $0.67. Bell Potter’s buy recommendation and recent price target of $2.00 following this release indicates a potential upside of roughly 194%.
Momentum Building in Commercial Execution
In a note out of the broker last Friday, Morgans provided an updated outlook on EBR Systems shares. The firm noted that 1Q26 delivered a step-change in commercial execution, with 41 implants (+128% q/q) and preliminary revenue of US$2.25-2.36m, materially ahead of prior run-rate.
Importantly, growth is being driven by repeat usage, not just new site additions, with the majority of 1Q implants coming from existing centres, supporting confidence in utilisation and scalability.
Morgans also highlighted that leading indicators remain strong, with 37 purchasing agreements, 55 physicians trained, and double-digit physician training demand, alongside emerging multi-site IDN/GPO contracts.
Buy Recommendation in Tact
Morgans also noted that the commercial bottleneck remains execution (sales capacity and contracting), not demand, with patient backlogs building and physician engagement “very high”. The firm made no changes to CY26-28 forecasts or A$2.47 DCF-based valuation, maintaining a BUY recommendation.
From last week’s closing price of $0.67, this target indicates an estimated upside of approximately 268%.
Considerations Before Investing
Before you buy EBR Systems, Inc. shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and EBR Systems, Inc. wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.
And right now, Scott thinks there are 5 stocks that may be better buys…
See the 5 Stocks
- Returns as of 20 Feb 2026
Additional Reading
- Where is the value amongst ASX healthcare shares?
- Bell Potter says this ASX healthcare stock could rise nearly 200%
- Why Bendigo Bank, EBR Systems, Strickland, and Woodside shares are rising today
- Experts name 2 ASX financials stocks to watch closely
- 3 ASX penny stocks drawing positive ratings from experts
Aaron Bell, a Motley Fool contributor, has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
